

PHARMACY PRE-AUTHORIZATION CRITERIA



DRUG (S)	Xadago (safinamide)
POLICY #	12123
INDICATIONS	Xadago is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.
CRITERIA	<p>ConnectiCare considers Xadago to be medically necessary when all of the following are met:</p> <ul style="list-style-type: none">• Patient has clinically diagnosed with Parkinson's Disease• Medication is being prescribed by, or in consultation with, a neurologist• Patient is currently using a levodopa-carbidopa combination• Patient must have had previous therapy with, contraindication, or intolerance to selegiline AND rasagiline• Patient is NOT currently using any of the following medications:<ul style="list-style-type: none">○ Other monoamine oxidase inhibitors or drugs that are potent inhibitors of monoamine oxidase (e.g., linezolid)○ Opioid drugs (e.g. tramadol, meperidine and related derivatives)○ Selective norepinephrine reuptake inhibitors (SNRIs)○ Tri-or tetra-cyclic or triazolopyridine antidepressants (trazodone)○ Cyclobenzaprine○ Methylphenidate, amphetamine, and their derivatives○ Dextromethorphan
LIMITATIONS	<p>Xadago has not been shown to be effective as monotherapy for Parkinson's Disease.</p> <p>Xadago is contraindicated in patients with severe hepatic impairment (Child-Pugh C: 10-15)</p>
REFERENCES	1. Xadago [package insert]. Louisville, KY: US WorldMeds, LLC; 2017.
P&T REVIEW HISTORY	8/17, 5/18, 5/19
REVISION RECORD	5/19